remeron smelt 15 mg smeltetabletter
merck sharp & dohme b.v. - mirtazapin - smeltetabletter - 15 mg
remeron smelt 30 mg smeltetabletter
merck sharp & dohme b.v. - mirtazapin - smeltetabletter - 30 mg
remeron smelt 45 mg smeltetabletter
merck sharp & dohme b.v. - mirtazapin - smeltetabletter - 45 mg
emerade 150 mikrogram injektionsvæske, opløsning i fyldt pen
pharmaswiss ceska republika s.r. - adrenalintartrat - injektionsvæske, opløsning i fyldt pen - 150 mikrogram
emerade 300 mikrogram injektionsvæske, opløsning i fyldt pen
pharmaswiss ceska republika s.r. - adrenalintartrat - injektionsvæske, opløsning i fyldt pen - 300 mikrogram
emerade 500 mikrogram injektionsvæske, opløsning i fyldt pen
pharmaswiss ceska republika s.r. - adrenalintartrat - injektionsvæske, opløsning i fyldt pen - 500 mikrogram
flucelvax tetra
seqirus netherlands b.v. - a/darwin/6/2021(h3n2)-like strain (a/darwin/11/2021, wild type) / a/wisconsin/67/2022 (h1n1)pdm09-like strain (a/georgia/12/2022 cvr-167) / b/austria/1359417/2021-like strain (b/singapore/wuh4618/2021) / b/phuket/3073/2013-like virus (b/singapore/inftt-16-0610/2016, wild type) - influenza, human - influenza, inaktiveret, split virus eller overflade antigen - prophylaxis of influenza in adults and children from 2 years of age. flucelvax tetra bør anvendes i overensstemmelse med officielle anbefalinger.
udenyca
era consulting gmbh - pegfilgrastim - neutropeni - immunostimulants, , koloni-stimulerende faktorer - reduktion i varigheden af neutropeni og forekomst af febril neutropeni hos voksne patienter behandlet med cytotoksisk kemoterapi for malignitet (med undtagelse af kronisk myeloid leukæmi og myelodysplastisk syndromer).
pluvicto
novartis europharm limited - lutetium (177lu) vipivotide tetraxetan - prostatic neoplasmer, kastration-resistent - terapeutiske radioaktive lægemidler - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.